Lat­est news on FDA’s sec­ond look at Amy­lyx; Un­pack­ing Parkin­son’s R&D; Fiona Mar­shall takes over NI­BR from Jay Brad­ner; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

This is go­ing to be a long week­end for us at End­points, thanks to La­bor Day in the US, and it’s much need­ed. Sep­tem­ber is shap­ing up to be a busy month, with bio­phar­ma seem­ing­ly com­ing back from the sum­mer and events kick­ing in­to gear. If you have any news to share, we al­ways ap­pre­ci­ate some lead time. For the dai­ly read­ers — see you on Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.